利拉鲁肽联合格列美脲治疗糖尿病的效果分析及对患者SF-36评分的影响  

Analysis on the efficacy of liraglutide combined with glimepiride in the treatment of diabetes mellitus and its effect on SF-36 score of patients

作　　者：俞俊萍[1] 丁红辉 陈霞[1] 何莉颖[1] 方明[1] 

机构地区：[1]浙江省义乌市中心医院内分泌科,浙江义乌322000 [2]浙江省义乌市妇幼保健院化验室,浙江义乌322000

出　　处：《中国现代医生》2018年第1期96-99,共4页China Modern Doctor

基　　金：浙江省医药卫生科技计划(2013KYA216)

摘　　要：目的探讨利拉鲁肽联合格列美脲治疗糖尿病的效果并分析其对患者SF-36评分的影响。方法从我院2014年7月~2016年7月收治的糖尿病患者中随机选取96例患者,依照随机数表法将他们分为研究组和对照组,各48例。对照组患者给予常规治疗,研究组患者在此基础上采用利拉鲁肽联合格列美脲进行治疗。治疗结束后对比两疗法对患者血糖指标、SF-36评分的影响,并比较两组临床治疗效果。结果治疗前两组患者的体质指数(BMI)、糖化性血红蛋白(Hb Alc)、餐后2 h血糖(2h PG)以及空腹血糖(FPG)等血糖指标无明显区别(P>0.05),治疗结束后两组患者BMI、Hb Alc、2h PG、FPG均降低,且研究组低于对照组(P<0.05);治疗前两组患者SF-36评分无明显区别(P>0.05),治疗结束后两组患者的SF-36评分显著提高,研究组高于对照组(P<0.05);临床疗效方面,研究组患者临床疗效明显优于对照组(P<0.05)。结论采用利拉鲁肽联合格列美脲治疗糖尿病效果十分显著,安全性有保障,能够有效改善改善患者健康状况,可在临床上大范围推广使用。Objective To investigate the efficacy of liraglutide combined with glimepiride in the treatment diabetes mellitus and its effect on SF-36 scores of patients. Methods From July 2014 to July 2016, 96 patients with diabetes mellitus who were admitted to our hospital were selected. According to the random number table method, they were divided into study group and control group, with 48 patients in each group. The control group was given conventional treatment, and the study group was given liraglutide combined with glimepiride on the basis of the control group. After the end of treatment, the effects of the two regimens on the blood glucose index and SF-36 score, and the clinical treatment effects were compared between the two groups. Results There were no significant differences in body mass index （BMI）, glycosylated hemoglobin （HbA1c）, postprandial 2 h blood glucose （2hPG） and fasting blood glucose （FPG） in the two groups before treatment（P〉0.05）. After treatment, BMI, HbAlc, 2hPG, and FPG were all reduced in both groups, and the study group was lower than the control group（P〈0.05）; there was no significant difference in SF-36 scores be tween the two groups before treatment（P〉0.05）, and at the end of treatment, the SF-36 score in the two groups was significantly improved. The study group was higher than the control group（P〈0.05）; the clinical efficacy in the study group was significantly better than that in the control group（P〈0.05）. Conclusion The application of liraglutide combined with glimepiride in the treatment of diabetes mellitus has a significant effect, and the safety is guaranteed, which can effectively improve the health condition of patients, and can be widely used and promoted in clinical practice.

关 键 词：糖尿病 利拉鲁肽 格列美脲 疗效分析 生活质量 

分 类 号：R587.1[医药卫生—内分泌]